GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

GMAB.DK

1,683

-1.72%↓

ZEAL.DK

312.39

-6.61%↓

AMBUB.DK

62.45

+0.24%↑

Home・Aktien・Novo Nordisk A-S (Class B)
Search

Novo Nordisk A-S (Class B)

Geschlossen

300.1 1.18

Buy

Kursupdate 13. Mai 2026, 14:54 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

299.85

Max

301.75

Schlüsselkennzahlen

By Trading Economics

Einkommen

22B

49B

Verkäufe

18B

97B

KGV

Branchendurchschnitt

11.012

51.415

EPS

10.91

Dividendenrendite

3.9

Gewinnspanne

50.15

Angestellte

67,900

EBITDA

32B

69B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+9.53% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.90%

2.34%

Nächstes Ergebnis

5. Aug. 2026

Nächstes Ex-Dividendendatum

13. Aug. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

84B

1.3T

Vorheriger Eröffnungskurs

298.92

Vorheriger Schlusskurs

300.1

Novo Nordisk A-S (Class B) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Mai 2026, 15:48 UTC

Akquisitionen, Fusionen, Übernahmen

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

DJ

Lesen

6. Mai 2026, 07:30 UTC

Ergebnisse

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

DJ

Lesen

6. Mai 2026, 06:19 UTC

Ergebnisse

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

DJ

Lesen

12. Mai 2026, 12:05 UTC

Heiße Aktien

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

DJ

Lesen

12. Mai 2026, 10:51 UTC

Heiße Aktien

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

DJ

Lesen

12. Mai 2026, 09:42 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

DJ

Lesen

12. Mai 2026, 09:08 UTC

Heiße Aktien

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

DJ

Lesen

11. Mai 2026, 20:30 UTC

Ergebnisse

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

DJ

Lesen

7. Mai 2026, 09:30 UTC

Ergebnisse

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

DJ

Lesen

6. Mai 2026, 12:36 UTC

Ergebnisse

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

DJ

Lesen

6. Mai 2026, 10:53 UTC

Heiße Aktien

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

DJ

Lesen

6. Mai 2026, 10:12 UTC

Ergebnisse

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

DJ

Lesen

6. Mai 2026, 09:58 UTC

Ergebnisse

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

DJ

Lesen

6. Mai 2026, 09:35 UTC

Heiße Aktien

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

DJ

Lesen

6. Mai 2026, 08:13 UTC

Market Talk
Ergebnisse

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

DJ

Lesen

6. Mai 2026, 07:43 UTC

Market Talk
Ergebnisse

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

DJ

Lesen

6. Mai 2026, 07:00 UTC

Ergebnisse

Novo Nordisk Shares Rise 5.5% After 1Q Results

DJ

Lesen

6. Mai 2026, 06:34 UTC

Ergebnisse

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

DJ

Lesen

6. Mai 2026, 06:26 UTC

Ergebnisse

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

DJ

Lesen

6. Mai 2026, 06:26 UTC

Ergebnisse

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

DJ

Lesen

6. Mai 2026, 06:24 UTC

Ergebnisse

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

DJ

Lesen

6. Mai 2026, 06:20 UTC

Ergebnisse

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

DJ

Lesen

6. Mai 2026, 06:19 UTC

Ergebnisse

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

DJ

Lesen

6. Mai 2026, 06:13 UTC

Ergebnisse

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

DJ

Lesen

6. Mai 2026, 06:13 UTC

Ergebnisse

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

DJ

Lesen

6. Mai 2026, 06:12 UTC

Ergebnisse

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

DJ

Lesen

6. Mai 2026, 05:43 UTC

Ergebnisse

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

DJ

Lesen

6. Mai 2026, 05:42 UTC

Ergebnisse

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

DJ

Lesen

6. Mai 2026, 05:40 UTC

Ergebnisse

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

DJ

Lesen

6. Mai 2026, 05:40 UTC

Ergebnisse

Novo Nordisk 1Q Op Margin 61.6%

DJ

Lesen

Peer-Vergleich

Kursveränderung

Novo Nordisk A-S (Class B) Prognose

Kursziel

By TipRanks

9.53% Vorteil

12-Monats-Prognose

Durchschnitt 1,162.73 DKK  9.53%

Hoch 1,550 DKK

Tief 720 DKK

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Novo Nordisk A-S (Class B) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

7

Buy

2

Halten

2

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Novo Nordisk A-S (Class B) – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Andere Aktien aus dem Sektor

GMAB.DK

Genmab A-S

1,683

↓-1.72%

ZEAL.DK

Zealand Pharma A-S

312.39

↓-6.61%

AMBUB.DK

Ambu A-S

62.45

↑ +0.24%
help-icon Live chat